

## E-cigarette use and Respiratory Symptoms in Residents of the United States: A BRFSS Report

Marcia H. Varella<sup>1¶</sup>, Olyn A. Andrade<sup>2&</sup>, Sydney M. Shaffer<sup>2&</sup>, Grettel Castro<sup>1&</sup>, Pura Rodriguez<sup>1&</sup>, Noël C. Barengo<sup>1,3,4¶</sup>, Juan M. Acuna<sup>56¶\*</sup>

<sup>1</sup>Department of Translational Medicine, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA

<sup>2</sup>American University of Antigua College of Medicine

<sup>3</sup>Department of Health Policy and Management, Robert Stempel College of Public Health and Social Work, Florida International University, Miami, FL, USA

<sup>4</sup>Department of Public Health, Faculty of Medicine, University of Helsinki, Finland

<sup>5</sup>Khalifa University, CMHS, Department of Epidemiology and Public Health. RDISC Aw 8474000331 AD, UAE

<sup>6</sup>CRUSADA, Robert Stempel College of Public Health and Social Work, Florida International University, Miami, FL, USA

<sup>¶</sup> These authors contributed equally to this work.

<sup>&</sup> These authors also contributed equally to this work.

\* Corresponding author: [Juan.acuna@ku.ac.ae](mailto:Juan.acuna@ku.ac.ae)

## 19 Abstract

20 **Purpose:** E-cigarettes are the most common type of electronic nicotine delivery system in the United States,  
21 rapidly gaining presence worldwide. E-cigarettes contain numerous toxic compounds that have been shown  
22 to induce mild to severe structural damage to the airways. The objective of this study is to assess if there is an  
23 association between e-cigarette use and respiratory symptoms in adults in the US as reported in the BRFSS in  
24 an attempt to drive potential early detection and prevention of severe or permanent respiratory disease.

25 **Methods:** We analyzed data from 18,079 adults, 18-44 years, who participated at the Behavioral Risk Factor  
26 Surveillance System (BRFSS) in the year 2017. E-cigarette smoking status was categorized as current  
27 everyday user, current some days user, former smoker, and never smoker. The frequency of any respiratory  
28 symptoms (cough, phlegm, or shortness of breath) was compared. We calculated unadjusted and adjusted  
29 odds ratios (OR) and 95% confidence intervals (CI).

30 **Results:** The BRFSS reported prevalence of smoking e-cigarettes was 6%. About 28% of the participants  
31 reported any of the respiratory symptoms assessed. The frequency of reported respiratory symptoms was  
32 highest among current some days e-cigarette users (45%). After adjusting for selected participant's  
33 demographic, socio-economic, and behavioral characteristics, and asthma and COPD status, the odds of  
34 reporting respiratory symptoms increased by 49% among those who use e-cigarettes some days (OR 1.49;  
35 95% CI: 1.06-2.11), and by 29% among those who were former users (OR 1.29; 95% CI: 1.07-1.55)  
36 compared with those who never used e-cigarettes. No statistically significant association was found for those  
37 who used e-cigarettes every day (OR 1.41; 95% CI 0.96-2.08)

38 **Conclusion:** E-cigarettes cannot be considered safe alternatives to combustible traditional cigarettes. Cohort  
39 studies may shed more evidence on the association between e-cigarette use and specific respiratory diseases.

40 **Key words:** E-cigarettes; Respiratory symptoms; Cough; Phlegm; Shortness of Breath; Lung disease; Young  
41 adults; Behavioral Risk Factor Surveillance System

## 43 Introduction

44 E-cigarettes use, or vaping was considered a safer alternative to conventional cigarettes and a potential  
45 alternative in tobacco smoking cessation efforts (1-3). It was introduced in the US marketplace in 2007 and  
46 since then its use has grown exponentially. Estimates based on the 2016-2017 Behavioral risk Factor  
47 Surveillance System (BRFSS) indicate a 4.4% prevalence of e-cigarette use for adults (18 years or older) (4,5)  
48 According to the National Youth Tobacco Survey (NYTS), e-cigarette use in 2020 for middle and high school  
49 students was estimated to be about 19.6 % and 4.7%, respectively (6).

50 The increase in the use of e-cigarettes is of concern. While e-cigarettes may reduce regular cigarette  
51 use, e-cigarette aerosol contains several toxic chemical constituents, including diacetyl or benzaldehyde, that  
52 negatively affect the respiratory system. (7,8). E-cigarette is also associated with wheezing, chronic cough,  
53 phlegm, or bronchitis in children and adults. (9-11). The results of a recently published systematic review  
54 estimated that the pooled OR associated with e-cigarette use for asthma was 1.39 (95% confidence interval  
55 (CI) 1.28-1.51) and for COPD was 1.49 (95% CI 1.36-1.65) (12).

56 While growing evidence points to detrimental respiratory effects of e-cigarettes use, just a few  
57 comparative studies assessed the effects of e-cigarettes in population-based, community-dwelling adults in the  
58 US(13-15). Additionally, the impact of e-cigarettes on the respiratory system has been assessed mainly by the  
59 report of asthma and or COPD, which could have underestimated the magnitude of the respiratory effects  
60 caused by e-cigarettes.

61 In this study, we assessed the association between e-cigarette use and the occurrence of respiratory  
62 symptoms (namely cough, phlegm production, or shortness of breath) as reported in the BRFSS, to obtain a  
63 more comprehensive understanding of the previous potentially underestimated impact of e-cigarette use in  
64 adults in the United States.

## 65 Methods

### 66 Design and setting

67 We used data from the 2017 BRFSS. Briefly, the BRFSS is an ongoing national yearly cross-sectional  
68 survey, originally aimed to identify emerging health problems to modify public health programs and policies.  
69 (16) It consists of phone-based interviews regarding participants' health-related risk behaviors, chronic health  
70 conditions, and use of preventive services. The inclusion criteria consisted of individuals between the ages of  
71 18-44 and those living within Arizona, the District of Columbia, Florida, Georgia, Minnesota, Nevada,  
72 Tennessee, and West Virginia. Only these states in the US collected information on the outcome of interest.

### 73 Study variables

74 E-cigarette usage (or vaping) was categorized as current everyday e-cigarette smokers, current someday e-  
75 cigarette smokers, former smokers, and those that never smoked, according to self-report. The outcome of  
76 interest was the presence of respiratory symptoms, considered present if the participant reported any of the  
77 following: cough, phlegm production occurring daily in the past three months, or shortness of breath hurrying  
78 on level ground or when walking up a slight hill or stairs. No report of these three symptoms was considered  
79 as an absence of the outcome. Covariates assessed included participant's age (assessed as a continuous  
80 variable and also categorized as either 18-34 or 35-44 years old), sex, race (White, Black, Hispanic, and  
81 "other"), employment status (employed, unemployed, student, and unable to work), education level (less than  
82 high school, high school graduate/General Educational Development exam completion, up to 3 years of  
83 college, and greater than 4 years of college), family yearly income ( $\leq 15,000$ ,  $>15,000$  to  $25,000$ ,  $>25,000$  to  
84  $35,000$ ,  $> 35,000$ - $50,000$ , and  $> 50,000$ ), marital status (married and unmarried), health insurance status  
85 (insured and uninsured), exercise reported in the past 30 days (yes, no), cigarette smoking status (current,  
86 former, never smoker), and history of ever being told to have asthma or chronic obstructive pulmonary  
87 disease.

## 88 Statistical analysis

89 A descriptive analysis was conducted to assess overall sample characteristics and to check for missing data  
90 patterns. Subsequently, bivariate analyses were done to further assess for potential confounders in the sample.  
91 Lastly, unadjusted and adjusted logistic regression analysis were conducted to estimate crude and adjusted  
92 odds ratios and corresponding 95% confidence intervals to explore and control for potential confounding  
93 variables and to determine potential interactions (effect modifiers). STATA v15 software was used for all  
94 analyses.<sup>11</sup> Further analyses restricted to participants who were never smokers and to those never reporting  
95 having asthma and COPD were performed.

96 This study does not require IRB clearance as it uses publicly available data from the CDC BRFSS.

## 97 Results

98 Of the 22,844 participants who completed the BRFSS questionnaire in the selected states in 2017,  
99 18,079 participants met our study inclusion criteria and were assessed. Table 1 displays the characteristics of  
100 participants according to e-cigarette use categories. Overall, never users of e-cigarettes were more frequently  
101 older, females, of minority race/ethnicity (African American and Hispanics), married, of higher education  
102 achievement (> 4 years of college) and higher income compared to all other e-cigarette users categories.  
103 Never users also reported less frequently smoking of traditional (combustible) cigarettes. For most  
104 comparisons, differences were more striking between never users and everyday e-cigarette users. The  
105 frequency of asthma and COPD report were highest for those who e-cigarettes use frequency was reported as  
106 “some days”. The overall frequency of the respiratory symptoms assessed was 27.6%. This frequency varied  
107 according to e-cigarette use categorization: it was highest for those reporting as *someday current users* and  
108 lowest for *never users* of e-cigarettes (44.6% and 23.3%, respectively, p-value <0.0001 for differences in at  
109 least one category) (Table 1).

110

**Table 1: Selected characteristics of the sample of participants of the BRFSS according to e-cigarette use**

		E-cigarette User category N (%)*				p-value
		Current every day	Current some days	Former	Never	
<b>Age (median and IQR)</b>		29 (23-36)	28 (22-36)	30 (25-36)	34 (27-39)	
<b>Age (in years, categories)</b>	18-34	315 (73.1)	539 (74.9)	2868 (72.3)	6648 (59.1)	<0.001
	35-44	134 (26.9)	220 (25.1)	1406 (27.7)	5949 (40.9)	
<b>Sex</b>	Male	309 (72.7)	437 (60.5)	2371 (58.9)	5574 (45.0)	0.002
	Female	140 (27.3)	322 (39.5)	1903 (41.1)	7019 (55.0)	
<b>Race/ethnicity</b>	White	359 (79.4)	525 (65.5)	2980 (63.8)	7632 (48.9)	<0.001
	Black	13 (3.2)	66 (13.0)	390 (11.3)	1745 (18.7)	
	Hispanic	34 (7.2)	105 (16.0)	580 (17.6)	2283 (24.6)	
	Other	43 (10.2)	63 (5.5)	324 (7.2)	937 (7.7)	
<b>Marital Status</b>	Married	187 (40.6)	264 (35.9)	1714 (38.1)	6767 (50.6)	<0.001
	Unmarried	258 (59.4)	493 (64.1)	2538 (61.9)	5752 (49.4)	
<b>Employment Status</b>	Employed	317 (72.6)	466 (58.2)	3028 (69.8)	9071 (70.5)	0.001
	Unemployed	54 (10.1)	139 (20.3)	616 (14.0)	1821 (15.5)	
	Student	44 (12.7)	96 (15.8)	362 (11.5)	1018 (10.7)	
	Unable to Work	29 (4.6)	48 (5.4)	215 (4.4)	473 (3.0)	
<b>Education achievement</b>	Up to high school	27 (8.8)	75 (16.6)	345 (12.4)	1029 (12.4)	<0.001
	≥High school/GED	172 (43.2)	307 (41.3)	1341 (31.9)	3133 (27.3)	
	≤3 years of college	173 (38.5)	269 (33.8)	1558 (39.2)	3469 (31.8)	
	> 4 years of college	75 (9.5)	108 (8.3)	1023 (16.5)	4933 (28.5)	
<b>Annual family income (\$)</b>	<15,000	33 (7.9)	78 (13.7)	364 (8.9)	972 (9.8)	0.001
	15,000-25,000	84 (23.1)	181 (28.3)	767 (22.7)	1833 (19.5)	
	25,000-35,000	59 (9.5)	76 (11.3)	470 (12.3)	1112 (11.3)	
	35,000-50,000	68 (20.2)	89 (17.3)	566 (15.1)	1539 (14.3)	
	>50,000	144 (39.2)	194 (29.3)	1488 (41.0)	5342 (45.1)	
<b>Health insurance status</b>	Insured	363 (80.0)	584 (71.5)	3391 (76.8)	10379 (79.0)	0.017
	Uninsured	83 (20.0)	163 (28.5)	857 (23.2)	2120 (21.0)	
<b>Exercised in past 30 days</b>	Yes	337 (70.5)	585 (80.3)	3208 (75.6)	9614 (75.8)	0.160
	No	110 (29.5)	173 (19.7)	1058 (24.4)	2967 (24.2)	
<b>Cigarette smoker status</b>	Current	133 (29.4)	434 (53.4)	1838 (42.2)	1092 (7.7)	<0.001
	Former	225 (46.2)	105 (14.5)	927 (20.5)	6094 (12.0)	
	Never	86 (24.4)	217 (32.1)	1486 (37.3)	9749 (80.2)	
<b>History of asthma</b>	Yes	80 (16.4)	173 (24.3)	836 (19.8)	1613 (12.9)	<0.001
	No	368 (83.6)	580 (75.7)	3425 (80.2)	10946 (87.1)	
<b>History of COPD</b>	Yes	19 (3.5)	65 (7.6)	231 (4.7)	292 (2.5)	<0.001
	No	429 (96.5)	687 (92.4)	4026 (95.3)	12276 (97.5)	
<b>Report of respiratory symptoms**</b>	Yes	159 (32.6)	320 (44.6)	1627 (36.3)	2882 (23.3)	<0.0001
	No	290 (67.4)	439 (55.4)	2647 (63.7)	9715 (76.7)	

\*Variables are reported as absolute count and % unless specified. \*\*Symptoms were self-reported and included cough, phlegm production, or shortness of breath. GED- general education diploma; COPD Chronic Obstructive Pulmonary Disease). P-value corresponding to difference for at least one e-cigarette use categories

111 Table 2 displays the crude and adjusted odds ratios (ORs) for participant's selected characteristics and  
 112 reported respiratory symptoms. In the unadjusted analyses, compared to the never users, all e-cigarette users

113 had significant increased odds of reporting respiratory symptoms. After controlling for confounding factors  
 114 (participant's demographic, socio-economic, behavioral -exercise and combustible cigarette use- asthma and  
 115 COPD status), the associations were attenuated and significant only for those reporting some days of e-  
 116 cigarette use and for former users compared to those who never used e-cigarettes (OR 1.49; 95% CI: 1.06-  
 117 2.11 and OR 1.29; 95% CI: 1.07-1.55, respectively). Other variables were also found independently associated  
 118 with the occurrence of respiratory symptoms; Females, Blacks, those with lower education, being unable to  
 119 work, family annual income lower than 50,000, being a current smoker, having no exercise reported in the  
 120 past 30 days, and reporting asthma were associated with higher odds for respiratory symptoms in the adjusted  
 121 analyses.

**Table 2. Associations between E-cigarette use, selected participant's characteristics and occurrence of respiratory symptoms in a sample of adults in the US participating at the BRFSS 2017**

Characteristics		Unadjusted		Adjusted	
		OR (95% CI)	p-value	OR (95% CI)	p-value
<b>E-cigarette Use</b>	Never	Reference		Reference	
	Current - every day	1.59 (CI 1.15-2.21)	0.005	1.41 (CI 0.96-2.08)	0.080
	Current - some days	2.65 (CI 2.04-3.46)	<0.001	1.49 (CI 1.06-2.11)	0.022
	Former user	1.88 (CI 1.64-2.16)	<0.001	1.29 (CI 1.07-1.55)	0.009
<b>Age (Years)</b>	35-44	Reference		Reference	
	18-34	1.04 (CI 0.92-1.17)	0.581	0.97 (CI 0.83-1.14)	0.754
<b>Sex</b>	Female	1.23 (CI 1.09-1.38)	0.001	1.27 (CI 1.08-1.48)	0.003
	<b>Race</b>	White	Reference	Reference	
	Black	1.19 (CI 1.00-1.41)	0.054	1.26 (CI 1.01-1.59)	0.043
	Hispanic	0.86 (CI 0.73-1.01)	0.066	0.87 (CI 0.70-1.07)	0.187
	Other	0.89 (CI 0.70-1.12)	0.316	1.07 (CI 0.77-1.47)	0.699
<b>Marital</b>	Married	Reference		Reference	
	Unmarried	1.36 (CI 1.21-1.54)	<0.001	1.09 (CI 0.93-1.28)	0.262
<b>Employment Status</b>	Employed	Reference		Reference	
	Unemployed	1.36 (CI 1.15-1.60)	<0.001	1.17 (CI 0.93-1.46)	0.179
	Unable to Work	4.26 (CI 3.27-5.56)	<0.001	2.47 (CI 1.76-3.48)	<0.001
<b>Education achievement</b>	> 4 years of college	Reference		Reference	
	Less than high school	2.94 (CI 2.39-3.60)	<0.001	1.72 (CI 1.28-2.30)	<0.001
	High school/GED	2.28 (CI 1.95-2.67)	<0.001	1.41 (CI 1.15-1.74)	0.001
	≤3 years of college	2.04 (CI 1.74-2.38)	<0.001	1.46 (CI 1.21-1.76)	<0.001
<b>Annual family income (\$)</b>	>50,000	Reference		Reference	
	<15,000	2.67 (CI 2.13-3.36)	<0.001	1.54 (CI 1.14-2.08)	0.005
	15,000-25,000	2.26 (CI 1.89-2.69)	<0.001	1.53 (CI 1.23-1.91)	<0.001
	25,000-35,000	1.61 (CI 1.30-2.00)	<0.001	1.27 (CI 0.99-1.62)	0.060
	35,000-50,000	1.85 (CI 1.50-2.27)	<0.001	1.51 (CI 1.21-1.88)	<0.001
<b>Health insurance status</b>	Insured	Reference		Reference	
	Uninsured	1.20 (CI 1.04-1.39)	0.014	0.89 (CI 0.73-1.08)	0.237
<b>No exercise in past 30 days</b>		1.59 (CI 1.39-1.82)	<0.001	1.41 (CI 1.20-1.67)	<0.001
<b>Cigarette Smokers status</b>	Never	Reference		Reference	
	Current	3.15 (2.72-3.66)	<0.001	1.99 (CI 1.62-2.44)	<0.001
	Former	1.24 (CI 1.04-1.48)	0.015	1.03 (CI 0.83-1.28)	0.791
<b>History of Asthma</b>		3.22 (CI 2.76-3.77)	<0.001	2.63 (CI 2.18-3.17)	<0.001
<b>History of COPD</b>		0.22 (CI 0.14-0.34)	<0.001	0.42 (CI 0.26-0.69)	0.001

---

BRFSS- Behavior Risk Factor Surveillance System; OR – odds ratio; CI – confidence interval. Adjusted model included all variables shown in the table

---

122 To study potential interactions, further analyses were conducted assessing the association between e-  
123 cigarette use, and respiratory symptoms occurrence in participants who were never smokers. The absolute  
124 number of participants who never smoked combustible cigarettes and were 86, 217, 1486, and 9749 for  
125 current every day, current some days, former, and never e-cigarette users, respectively. In this analysis, the  
126 only significant increased odds for respiratory symptoms were found for former e-cigarette users compared to  
127 never users (supplemental table 1). Lastly, exclusion of participants with prior history of asthma and COPD  
128 did not affect the estimates of the associations reported for e-cigarette and respiratory symptoms compared to  
129 the analyses where those conditions were adjusted for (supplemental table 2).

## 130 Discussion

131 Our data revealed that 2.5% and 4.2% of the sample subjects were *every day* or *some days* e-cigarette  
132 users, respectively. Overall, respiratory symptoms (cough, phlegm production, or shortness of breath) were  
133 reported in approximately 28% of the sample, a much higher frequency than those symptoms previously  
134 reported in another research. (9-11) Compared to never users, e-cigarette use was associated with up to 50%  
135 increased odds of respiratory symptoms; the highest odds were found for those using some day, followed by  
136 former users of e-cigarette.

137 While previous research demonstrated that even short-term exposure to e-cigarettes and their toxic  
138 compounds produced cough and phlegm in healthy individuals and individuals with a history of asthma,<sup>7</sup> most  
139 of the previous cross-sectional and longitudinal studies in US adults that were published, assessed the  
140 detrimental effects of e-cigarettes focusing on outcomes such as asthma and COPD occurrence (12,13,15,17).  
141 Our results for someday e-cigarette users suggesting a 49% increase in odds for the outcome, a composite of  
142 cough, phlegm production, or shortness of breath, were consistent in magnitude with the previous studies,  
143 despite assessing associations independently of COPD, asthma status, and demographic, socio-economic, and  
144 clinical characteristics. For instance, in the meta-analyses reported in the integrative review published in 2021



145 by Wills et al, the pooled odds of asthma and COPD were 39% (OR=1.39, 95% CI 1.28-1.51) and 49%  
146 (OR1.49, 95% CI=1.36-1.65) higher, respectively, for e-cigarette users compared to never users (12). A less  
147 marked increase in the odds of cough or phlegm has also been reported in Chinese adolescents in 2012-2013,  
148 with e-cigarette users having 1.28 times higher odds to develop symptoms compared to non-users (regardless  
149 of other combustible smoking habits). (11) Our results suggest that increases symptoms occur, and are  
150 independent of asthma and COPD diagnosis. We also attempted to further assess for potential gradient in the  
151 risk according to the frequency of e-cigarette use and our findings indicate that - while for current everyday  
152 users the magnitude of the association seemed like the one found for some day users - results were no longer  
153 significant after adjustments. It is possible that the smaller number of participants (about 40% less than some  
154 days users) might have contributed to the lack of statistical significance. Prospective studies including larger  
155 number of e-cigarette users are needed to better understand causality better, and to define whether a dose-  
156 response gradient exists for the risk of e-cigarettes use and respiratory symptoms.

157 E-cigarettes are designed to deliver nicotine throughout the body, without the combustion of tobacco.  
158 Through inhalation of water vapor to the lungs, numerous toxic compounds like those found within  
159 conventional cigarettes are released within the body. Examples of these compounds are aldehydes  
160 (formaldehyde and acrolein) and e-liquids (propylene glycol and glycerol). (7,8,18) Overtime, these  
161 chemicals cause an elevated mucin concentration and result in failed mucus transport, hallmarks seen in  
162 patients of COPD (Chronic Obstructive Pulmonary Disease). The chemicals within e-cigarettes also stimulate  
163 neutrophils, resulting in the release of myeloperoxidase (MPO), neutrophil elastase (NE), and other granular  
164 proteins. The amount of proteins released in e-cigarettes is double to what was described for conventional  
165 cigarettes, and it causes massive structural damage to airways. (19) These changes could explain potential  
166 mechanism that contribute to the common symptoms of chronic cough, phlegm, and shortness of breath  
167 observed in e-cigarette users.

168 This study large sample size and the use of systematically collected and comprehensive information  
169 from participants from multiple states contribute to increase study's generalizability when representing the  
170 adult population in the US. There are some limitations inherent to the cross-sectional and self-reported nature  
171 of the survey, and they should be discussed. First, we lack detailed information on the timing when e-cigarette  
172 and the symptoms occurred. The BRFSS survey inquired about cough and phlegm occurring in the three  
173 months preceding the survey, while e-cigarettes use status referred to the time of the survey. Therefore, the  
174 extent of which potential reverse causality accounts for the association described is unknown, and prospective  
175 studies are warranted. Furthermore, given the responses were based on self-report, misclassifications of both  
176 exposure to e-cigarettes and occurrence of symptoms are possible. While we do not have evidence to help us  
177 to estimate the directionality of the bias, we believe that both the frequency of symptoms and of e-cigarettes  
178 would be underreported, thus, most likely biasing the association towards the null hypothesis.

179 In conclusion, our results also suggest that e-cigarettes might increase the risk of detrimental  
180 respiratory symptoms, but the dose-effect relationship is yet to be confirmed with more accurate assessment  
181 of e-cigarette exposure levels. Therefore, our study adds to the growing body of literature suggesting that e-  
182 cigarettes are not safe alternatives for smoking cessation interventions.

## 183 References

- 184 (1) Hartmann-Boyce J, McRobbie H, Lindson N, Bullen C, Begh R, Theodoulou A, et al. Electronic  
185 cigarettes for smoking cessation. *Cochrane Database Syst Rev* 2021 Apr 29;4:CD010216.
- 186 (2) Cahn Z, Siegel M. Electronic cigarettes as a harm reduction strategy for tobacco control: a step  
187 forward or a repeat of past mistakes? *J Public Health Policy* 2011 Feb;32(1):16-31.
- 188 (3) Polosa R, Caponnetto P, Maglia M, Morjaria JB, Russo C. Success rates with nicotine personal  
189 vaporizers: a prospective 6-month pilot study of smokers not intending to quit. *BMC Public Health*  
190 2014 Nov 8;14:1159-2458-14-1159.

- 191 (4) Du Y, Liu B, Xu G, Rong S, Sun Y, Wu Y, et al. Association of Electronic Cigarette Regulations  
192 With Electronic Cigarette Use Among Adults in the United States. JAMA Netw Open 2020 Jan  
193 3;3(1):e1920255.
- 194 (5) Mirbolouk M, Charkhchi P, Kianoush S, Uddin SMI, Orimoloye OA, Jaber R, et al. Prevalence  
195 and Distribution of E-Cigarette Use Among U.S. Adults: Behavioral Risk Factor Surveillance System,  
196 2016. Ann Intern Med 2018 Oct 2;169(7):429-438.
- 197 (6) Gentzke AS, Wang TW, Jamal A, Park-Lee E, Ren C, Cullen KA, et al. Tobacco Product Use  
198 Among Middle and High School Students - United States, 2020. MMWR Morb Mortal Wkly Rep  
199 2020 Dec 18;69(50):1881-1888.
- 200 (7) Allen JG, Flanigan SS, LeBlanc M, Vallarino J, MacNaughton P, Stewart JH, et al. Flavoring  
201 Chemicals in E-Cigarettes: Diacetyl, 2,3-Pentanedione, and Acetoin in a Sample of 51 Products,  
202 Including Fruit-, Candy-, and Cocktail-Flavored E-Cigarettes. Environ Health Perspect 2016  
203 Jun;124(6):733-739.
- 204 (8) Armendariz-Castillo I, Guerrero S, Vera-Guapi A, Cevallos-Vilatuna T, Garcia-Cardenas JM,  
205 Guevara-Ramirez P, et al. Genotoxic and Carcinogenic Potential of Compounds Associated with  
206 Electronic Cigarettes: A Systematic Review. Biomed Res Int 2019 Dec 19;2019:1386710.
- 207 (9) McConnell R, Barrington-Trimis JL, Wang K, Urman R, Hong H, Unger J, et al. Electronic  
208 Cigarette Use and Respiratory Symptoms in Adolescents. Am J Respir Crit Care Med 2017 Apr  
209 15;195(8):1043-1049.
- 210 (10) Tackett AP, Keller-Hamilton B, Smith CE, Hebert ET, Metcalf JP, Queimado L, et al. Evaluation  
211 of Respiratory Symptoms Among Youth e-Cigarette Users. JAMA Netw Open 2020 Oct  
212 1;3(10):e2020671.
- 213 (11) Wang MP, Ho SY, Leung LT, Lam TH. Electronic Cigarette Use and Respiratory Symptoms in  
214 Chinese Adolescents in Hong Kong. JAMA Pediatr 2016 Jan;170(1):89-91.

- 215 (12) Wills TA, Soneji SS, Choi K, Jaspers I, Tam EK. E-cigarette use and respiratory disorders: an  
216 integrative review of converging evidence from epidemiological and laboratory studies. *Eur Respir J*  
217 2021 Jan 21;57(1):10.1183/13993003.01815-2019. Print 2021 Jan.
- 218 (13) Osei AD, Mirbolouk M, Orimoloye OA, Dzaye O, Uddin SMI, Dardari ZA, et al. The association  
219 between e-cigarette use and asthma among never combustible cigarette smokers: behavioral risk factor  
220 surveillance system (BRFSS) 2016 & 2017. *BMC Pulm Med* 2019 Oct 16;19(1):180-019-0950-3.
- 221 (14) Mirbolouk M, Charkhchi P, Orimoloye OA, Uddin SMI, Kianoush S, Jaber R, et al. E-Cigarette  
222 Use Without a History of Combustible Cigarette Smoking Among U.S. Adults: Behavioral Risk  
223 Factor Surveillance System, 2016. *Ann Intern Med* 2019 Jan 1;170(1):76-79.
- 224 (15) Bhatta DN, Glantz SA. Association of E-Cigarette Use With Respiratory Disease Among Adults:  
225 A Longitudinal Analysis. *Am J Prev Med* 2020 Feb;58(2):182-190.
- 226 (16) Centers for Disease Control and Prevention (CDC). Behavioral Risk Factor Surveillance System.  
227 Aug 30th, 2021; Available at: <https://www.cdc.gov/brfss/>. Accessed 09/21/2021.
- 228 (17) Barrameda R, Nguyen T, Wong V, Castro G, Rodriguez de la Vega P, Lozano J, et al. Use of E-  
229 Cigarettes and Self-Reported Lung Disease Among US Adults. *Public Health Rep* 2020  
230 Nov/Dec;135(6):785-795.
- 231 (18) Thirion-Romero I, Perez-Padilla R, Zabert G, Barrientos-Gutierrez I. Respiratory Impact of  
232 Electronic Cigarettes and "Low-Risk" Tobacco. *Rev Invest Clin* 2019;71(1):17-27.
- 233 (19) Reidel B, Radicioni G, Clapp PW, Ford AA, Abdelwahab S, Rebuli ME, et al. E-Cigarette Use  
234 Causes a Unique Innate Immune Response in the Lung, Involving Increased Neutrophilic Activation  
235 and Altered Mucin Secretion. *Am J Respir Crit Care Med* 2018 Feb 15;197(4):492-501.

## 236 Acknowledgments

237 We thank the Behavior Risk Factor Surveillance System (BRFSS) working group and the survey  
238 participants for their contribution.

239

240

241

242

243

244

245

246

247

248

249

250

251